Retatrutide Side Effects: What the Trials Show

If you've been reading about the next generation of weight loss injections, you've probably come across retatrutide — and your very next thought was likely about what it does to your body beyond the weight loss. That's a sensible instinct. Any medication powerful enough to produce the kind of results retatrutide has shown in trials is going to come with trade-offs, and understanding those trade-offs properly is how you make an informed decision.

Retatrutide is still in clinical trials, so we don't yet have the full picture that comes with years of real-world prescribing. But the Phase 2 trial data published in the New England Journal of Medicine gives us a detailed look at what participants experienced.

How retatrutide works

Before getting into the specifics, it helps to understand what retatrutide actually does, because the side effect profile follows directly from its mechanism.

Most weight loss injections you'll have heard of — Wegovy (semaglutide) and Mounjaro (tirzepatide) — work on one or two gut hormone receptors. Retatrutide works on three: GLP-1, GIP and glucagon. That triple action is what produced the profound weight loss figures in trials (up to 24% body weight reduction at the highest dose over 48 weeks), but it also means the medication is doing more things in your body simultaneously.

The GLP-1 component slows gastric emptying and reduces appetite, which is the main source of the GI side effects. The glucagon component increases energy expenditure and has effects on the liver. The GIP component influences how your body handles fat storage. Each of these pathways can produce its own set of effects.

Common retatrutide side effects from the Phase 2 trial

The largest published study on retatrutide — the Phase 2 trial by Jastreboff et al., published in the NEJM in 2023 — enrolled 338 adults with obesity. Participants received varying doses (1mg, 4mg, 8mg or 12mg) or placebo, and were followed for 48 weeks.

The pattern that emerged is consistent with what we see with other GLP-1-based medications, though the triple mechanism adds a few distinctive features.

Gastrointestinal effects

These were by far the most commonly reported side effects, and they're the ones most people will want to know about.

Heart rate changes

This is where retatrutide differs from some of its predecessors in a clinically meaningful way.

The Phase 2 trial found a dose-dependent increase in resting heart rate. At the 12mg dose, the average increase was around 2.6–6.7 beats per minute compared to baseline, peaking at approximately 24 weeks. After that peak, heart rates tended to stabilise or decrease slightly, even as participants remained on the medication.

To put that in perspective: an increase of 4–6 bpm is relatively modest. Your heart rate naturally fluctuates by more than that throughout the day depending on activity, stress and caffeine intake. The trial investigators noted that the increase was not associated with any cardiovascular adverse events during the study period.

That said, this is an area where longer-term data will be important. Phase 3 trials are specifically monitoring cardiovascular outcomes, and anyone with a pre-existing heart condition would need careful assessment before starting retatrutide — assuming it gains approval.

Skin sensitivity and tingling

This is a side effect that's fairly specific to retatrutide and isn't commonly seen with semaglutide or tirzepatide.

Around 7% of participants in the Phase 2 trial reported what researchers described as "treatment-emergent skin sensitivity" — sensations like tingling, burning or increased sensitivity to touch. The mechanism isn't fully understood, but it may be related to the glucagon receptor activity, which is the component that sets retatrutide apart from dual agonists like Mounjaro.

The good news: these skin sensations were generally rated as mild, and no participants withdrew from the trial because of them. Most reported that the sensations diminished over time without any specific treatment.

Injection site reactions

As with any subcutaneous injection, some participants experienced reactions at the injection site — redness, mild swelling or discomfort. This affected roughly 4–5% of participants across dosing groups. These reactions were universally mild and resolved on their own.

If you're already using a GLP-1 injection like Wegovy or Mounjaro, the injection experience with retatrutide would feel very familiar.

Retatrutide side effects on the liver

Liver-related effects are worth addressing separately because they're an area of clinical interest and one that tends to generate anxiety when people read about it online.

The Phase 2 trial found that some participants experienced temporary increases in liver enzymes (specifically ALT and AST). These are markers that can indicate liver stress, and seeing them rise understandably raises concern.

However, the context is important. Mild elevations in liver enzymes are common with significant weight loss from any cause — including bariatric surgery and even intensive dietary programmes. When the body rapidly mobilises fat stores, some of that fat passes through the liver, and enzyme levels can temporarily tick upward.

In the retatrutide trial, these elevations were transient and returned to normal without intervention. No cases of clinically significant liver injury were reported. In fact, some researchers have noted that retatrutide's glucagon activity may actually be beneficial for liver fat — early data suggests it could reduce hepatic steatosis (fatty liver disease), which is extremely common in people with obesity.

This is an area where Phase 3 data will provide much more clarity. For now, anyone starting retatrutide would likely have routine liver function tests as part of their monitoring — which is standard good practice with any new medication.

Retatrutide and kidney function

Kidney concerns often come up in discussions about GLP-1 medications, partly because dehydration from GI side effects (particularly vomiting and diarrhoea) can theoretically affect kidney function.

In the Phase 2 trial, there were no significant signals of kidney impairment attributable to retatrutide. The standard advice applies: staying well hydrated is important, especially during the early weeks when GI side effects are more likely. If you experience persistent vomiting or severe diarrhoea, that warrants a conversation with your prescriber.

People with pre-existing kidney disease would need individual assessment — this is true for all GLP-1-based medications, not just retatrutide.

Does retatrutide increase cancer risk?

This question comes up frequently, and it's worth addressing head-on.

The concern originates from preclinical (animal) studies of GLP-1 receptor agonists, which found an increased incidence of thyroid C-cell tumours in rodents. This has been observed across the GLP-1 class — including semaglutide and liraglutide — and it's the reason these medications carry a boxed warning about medullary thyroid carcinoma in the US.

However, the relevance to humans is uncertain. Rodent thyroid C-cells respond to GLP-1 stimulation in a way that human C-cells largely do not. After more than a decade of real-world use of GLP-1 medications in millions of patients, there has been no established increase in thyroid cancer risk in humans.

For retatrutide specifically, the Phase 2 trial was too short and too small to draw meaningful conclusions about cancer risk. This is exactly the kind of question that requires large, long-term pharmacovigilance data. As a precaution, retatrutide would likely carry the same class-level thyroid warnings as other GLP-1 medications, and it would not be recommended for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Retatrutide side effects on fertility

Another frequently searched question — particularly by women of childbearing age, who make up a significant proportion of people considering weight loss medication.

The honest answer: we don't have enough data yet. The Phase 2 trial did not specifically study fertility outcomes, and animal reproductive toxicity studies are typically part of the broader Phase 3 programme.

What we do know from the broader GLP-1 class is that weight loss itself can improve fertility in women with obesity-related conditions like PCOS. There's also evidence that GLP-1 agonists can reduce the effectiveness of oral contraceptives by slowing gastric emptying — a practical consideration that's easy to overlook.

Until more data is available, the standard guidance is that retatrutide should not be used during pregnancy, and women should use reliable non-oral contraception while taking it.

Long-term side effects of retatrutide

The 48-week Phase 2 trial is the longest published data we have. That's enough time to observe short-to-medium-term effects, but not enough to answer questions about what happens after years of use.

Key unknowns include:

• Whether the heart rate increase persists, resolves or has any long-term cardiovascular implications
• The full effect on liver and metabolic health over extended treatment
• Whether bone density is affected (significant weight loss can reduce bone mineral density regardless of the method)
• Any potential effects on the pancreas — pancreatitis has been a monitored concern across all GLP-1 medications
• What happens when someone stops taking retatrutide (weight regain patterns, metabolic rebound)

Phase 3 trials, including the large TRIUMPH programme, are designed to answer many of these questions. Until that data is published, anyone considering retatrutide needs to weigh the significant short-term benefits against this uncertainty — a conversation that should happen with a qualified prescriber, not on a forum.

How retatrutide side effects compare to Wegovy and Mounjaro

One of the most useful ways to understand retatrutide's side effect profile is by comparing it to medications already available.

What's striking is that despite being a more potent weight loss agent, retatrutide's GI side effect rates in the Phase 2 trial were actually lower than those reported in the pivotal trials for semaglutide (Wegovy).

The unique side effects — heart rate increase and skin sensitivity — are the main differentiators. Whether these prove clinically significant in the long term will depend on Phase 3 data.

Managing retatrutide side effects

While we wait for retatrutide to complete its clinical programme and potentially gain approval, the management strategies are likely to mirror what works well for existing GLP-1 medications:

For nausea and GI symptoms:

• Eat smaller portions more frequently rather than large meals
• Avoid fatty, greasy or heavily spiced food, particularly during dose-escalation weeks
• Eat slowly and stop when you feel comfortable — not full
• Stay upright after eating; lying down can worsen nausea
• Ginger tea or peppermint can help mild nausea for some people

For constipation:

• Increase fibre intake gradually (not suddenly — that can make things worse)
• Drink plenty of water throughout the day
• Gentle physical activity helps keep things moving

For injection site reactions:

• Rotate injection sites (abdomen, thigh, upper arm)
• Ensure the medication is at room temperature before injecting
• Use proper injection technique — your prescriber or pharmacist can demonstrate this

For skin sensitivity:

• This generally resolves without treatment
• If bothersome, loose-fitting clothing and avoiding very hot showers may help
• Report persistent or worsening symptoms to your prescriber

When to seek medical attention

Most retatrutide side effects are mild and self-limiting. But certain symptoms warrant prompt medical review:

• Severe or persistent vomiting that prevents you from keeping fluids down
• Intense abdominal pain (particularly if it radiates to the back — this could indicate pancreatitis)
• Signs of an allergic reaction: swelling of the face, lips or tongue, difficulty breathing, severe rash
• A lump or swelling in the neck, hoarseness or difficulty swallowing (potential thyroid concern)
• Yellowing of the skin or eyes (jaundice — a sign of significant liver involvement)
• Symptoms of low blood sugar if you're also taking insulin or sulphonylureas: shakiness, sweating, confusion

This isn't a reason to be alarmed — these serious events were rare in trials. But knowing what to watch for means you can act quickly if needed.

The bottom line

Retatrutide's Phase 2 data paints a picture of a medication with impressive efficacy and a side effect profile that is broadly manageable — mostly GI symptoms that settle with time, plus some distinctive effects on heart rate and skin that need watching. The big unknowns are long-term safety and what Phase 3 trials will reveal.

If you're interested in retatrutide, the most important thing right now is understanding that it's not yet available as an approved treatment. In the meantime, proven weight loss medications like Wegovy and Mounjaro are available — and your prescriber can help you find the right option based on your individual health profile.

For a broader look at where retatrutide fits in the UK treatment picture, read our guide to retatrutide availability, safety and alternatives.

Frequently asked questions

What are the most common retatrutide side effects?

The most frequently reported side effects in clinical trials were gastrointestinal — nausea, diarrhoea, vomiting and constipation. These are dose-dependent (more common at higher doses) and tend to occur during the dose-escalation phase. Most cases were mild to moderate and resolved as participants adjusted to the medication.

Does retatrutide cause heart problems?

The Phase 2 trial showed a modest, dose-dependent increase in resting heart rate of approximately 4–6 beats per minute at the highest dose, peaking around 24 weeks. No cardiovascular adverse events were attributed to this increase during the trial period. Phase 3 trials are specifically monitoring cardiovascular outcomes for more definitive answers.

Can retatrutide damage your liver?

Some participants experienced temporary increases in liver enzymes, which is common during rapid weight loss from any cause. These elevations were mild, transient and resolved without intervention. Early data actually suggests retatrutide may help reduce liver fat. Routine liver function monitoring would be expected as part of treatment.

Is retatrutide safe long-term?

We don't know yet. The longest published data covers 48 weeks. Key unknowns include long-term cardiovascular effects, bone density changes, and pancreatic safety. Phase 3 trials are designed to answer these questions, and results are expected in the coming years.

How do retatrutide side effects compare to Wegovy?

Despite producing greater weight loss, retatrutide's GI side effect rates in Phase 2 were lower than those reported in Wegovy's pivotal trials. Nausea affected around 16% of participants on the highest retatrutide dose compared to approximately 44% with Wegovy. However, retatrutide does cause some effects not typically seen with Wegovy, including a small increase in heart rate and skin sensitivity.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.